RTP Mobile Logo

Interview with Daniel J DeAngelo, MD, PhD

Track 1: Case: A 21-year-old woman presents with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia (ALL) and is found to have an E2A-Pbx1 translocation
Track 2: Biologic rationale for the use of pediatric regimens for young adult patients with ALL
Track 3: Importance of Philadelphia chromosome status and Philadelphia-like signature in prognosis and treatment approach
Track 4: Cooperative care of patients with ALL between community practices and tertiary centers
Track 5: Treatment selection strategy for patients with ALL
Track 6: Comparison of treatment strategies for young adults with ALL
Track 7: Evolution of multiagent regimens in pediatric ALL
Track 8: Asparaginase preparations for ALL
Track 9: Activity and tolerability of inotuzumab ozogamicin
Track 10: Recognition and management of immune-related side effects of blinatumomab
Track 11: Cytokine release syndrome and neurotoxicity with chimeric antigen receptor T-cell (CAR-T) therapy
Track 12: Anticipated role of CAR-T therapy in clinical practice and potential integration into treatment algorithms for ALL
Track 13: Limitations of current diagnostic technology for ALL in the community setting
Track 14: Case: A 35-year-old man presents with fatigue, fever and chills and is diagnosed with FLT3-ITD-negative acute myeloid leukemia (AML)
Track 15: Mechanism of action and efficacy of midostaurin for patients with FLT3 mutation-positive AML
Track 16: Investigational FLT3 inhibitors in AML
Track 17: Liposomal cytarabine/daunorubicin (CPX-351) for secondary AML
Track 18: IDH1/2 inhibitors for AML
Track 19: Efficacy of venetoclax alone and in combination with hypomethylating agents for AML
Track 20: Early data with the use of hedgehog inhibitors for AML
Track 21: Voluntary market removal of gemtuzumab ozogamicin and the potential for reintroduction
Track 22: Side effects and toxicities of the antibody-drug conjugate vadastuximab talirine in patients with AML

Interview with Amir T Fathi, MD

Track 1: Overview of new agents for AML
Track 2: Cytogenetic evolution between AML diagnosis and relapse and effects on reinduction therapy outcomes
Track 3: FLT3 inhibitors for relapsed/refractory AML
Track 4: Hypomethylating agents in older patients with AML
Track 5: Therapeutic options after treatment with hypomethylating agents for older patients with AML
Track 6: Specificity and toxicity of various FLT3 inhibitors
Track 7: Phase III RATIFY study: Midostaurin with daunorubicin/cytarabine induction therapy, with high-dose cytarabine consolidation and as maintenance therapy for newly diagnosed FLT3 mutation-positive AML
Track 8: Recognition and management of differentiation syndromes in patients with AML treated with IDH or FLT3 inhibitors
Track 9: Biologic rationale for targeting IDH1/2 mutations
Track 10: Efficacy and tolerability of the IDH inhibitors enasidenib and ivosidenib in patients with IDH mutations
Track 11: CPX-351 and venetoclax in AML
Track 12: Current status of the investigational hedgehog inhibitor glasdegib and the antibody-drug conjugate gemtuzumab ozogamicin
Track 13: CAR-T therapy and the aurora A kinase inhibitor alisertib for AML
Track 14: Case: A 50-year-old man with FLT3 wild-type myelodysplastic syndrome experiences disease transformation to FLT3-ITD mutation-positive AML
Track 15: Case: A 56-year-old man with heavily pretreated AML and a FLT3-ITD mutation receives sorafenib
Track 16: Conventional treatments and emerging therapies for ALL
Track 17: Case: A 55-year-old woman with relapsed Philadelphia chromosome-negative B-cell ALL receives blinatumomab
Track 18: Neurologic toxicities with blinatumomab in the treatment of ALL
Track 19: Toxicity with different preparations of asparaginase in older patients with ALL
Track 20: Case: A 45-year-old man with low-risk acute promyelocytic leukemia initially treated with all-trans retinoic acid and arsenic trioxide develops differentiation symptoms
Daniel J DeAngelo, MD, PhD
Director of Clinical and
Translational Research
Adult Leukemia
Institute Physician
Associate Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts
Amir T Fathi, MD
Assistant Professor of Medicine
Harvard Medical School
Massachusetts General Hospital
Boston, Massachusetts
Neil Love, MD
Research To Practice
Miami, Florida